title: Early and late effects of rt-PA vs placebo on left ventricular function measured by nuclear ventriculography.
abstract: The aim of the study was the functional re-evaluation of 296 patients 12 to 18 months after a double-blind trial evaluating the effect of tissue plasminogen activator (rt-PA) versus placebo given within 5 h of onset of symptoms caused by an acute myocardial infarction. All patients underwent rest-stress radionuclide angiography (Egna). For each exercise level the global left ventricular ejection fraction (LVEF) was calculated together with an estimate of regional wall motion abnormalities (RWMA). A clear difference of the total workload and the peak workload was found between both therapeutic groups. Discriminant analysis evaluating four parameters (LVEF at peak exercise and at the endpoint and the workload at those levels) revealed a beneficial therapeutic effect. The RWM at rest showed only a difference in the apico-inferior region. There were less wall motion abnormalities in the treated group. Radionuclide analysis demonstrated a larger functional capacity and a better coordination of myocardial contractility during stress RNA one year after thrombolytic therapy. At rest, no major differences were found between the hospital stage and the follow-up in both therapeutic groups one year later.
authors.affiliation: Department of Nuclear Medicine, University Hospital, Leuven, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Mortelmans
authors.forename: I
authors.initials: I
authors.lastname: Scheys
authors.forename: T
authors.initials: T
authors.lastname: Brzostek
authors.forename: E
authors.initials: E
authors.lastname: Lesaffre
authors.forename: M
authors.initials: M
authors.lastname: De Roo
authors.forename: M
authors.initials: M
authors.lastname: Verstraete
authors.forename: H
authors.initials: H
authors.lastname: De Geest
authors.forename: F
authors.initials: F
authors.lastname: Van de Werf
mesh_terms: D000328:Adult; D000368:Aged; D001530:Belgium / Q000453:epidemiology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D013668:Technetium Tc 99m Aggregated Albumin; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D013668:Technetium Tc 99m Aggregated Albumin; D010959:Tissue Plasminogen Activator